17.06
전일 마감가:
$16.66
열려 있는:
$16.5
하루 거래량:
166.75K
Relative Volume:
0.82
시가총액:
$568.23M
수익:
$65.42M
순이익/손실:
$-32.96M
주가수익비율:
-13.43
EPS:
-1.27
순현금흐름:
$-19.87M
1주 성능:
+3.39%
1개월 성능:
+81.49%
6개월 성능:
+29.54%
1년 성능:
+52.46%
뉴로페이스 Stock (NPCE) Company Profile
명칭
Neuropace Inc
전화
(650) 237-2700
주소
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
NPCE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
NPCE
Neuropace Inc
|
17.06 | 554.91M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
125.40 | 217.86B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.72 | 146.12B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
364.35 | 139.95B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.99 | 130.73B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.78 | 48.73B | 5.88B | 1.34B | 799.60M | 2.3489 |
뉴로페이스 Stock (NPCE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-01-21 | 개시 | UBS | Buy |
| 2024-03-14 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | 개시 | Leerink Partners | Outperform |
| 2023-11-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-08-24 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | 개시 | Lake Street | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-01-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | 개시 | Robert W. Baird | Outperform |
| 2021-05-17 | 개시 | JP Morgan | Overweight |
| 2021-05-17 | 개시 | Morgan Stanley | Overweight |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-17 | 개시 | Wells Fargo | Overweight |
모두보기
뉴로페이스 주식(NPCE)의 최신 뉴스
Published on: 2025-12-04 13:47:14 - Newser
Is NeuroPace Inc. stock ready for breakoutJuly 2025 Summary & Free Long-Term Investment Growth Plans - Newser
Baird Medical Appoints Mark Saxton as U.S. CEO; Taps Veteran from NeuroPace, Smith + Nephew, and Covidien to Lead Commercial Expansion - PR Newswire
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting - BioSpace
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society Annual Meeting - Investing News Network
Why analysts remain bullish on NeuroPace Inc. stockM&A Rumor & Technical Entry and Exit Alerts - Newser
Will NeuroPace Inc. stock deliver consistent dividendsWeekly Stock Recap & High Yield Equity Trading Tips - Newser
NeuroPace (NASDAQ:NPCE) Trading Down 4.1%Should You Sell? - MarketBeat
NeuroPace announces Medicare reimbursement increases for RNS System - MSN
NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Why NeuroPace, Inc. (NASDAQ:NPCE) Could Be Worth Watching - 富途牛牛
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates - MSN
NeuroPace NPCE insider updates holdings after RSU tax withholding - Stock Titan
Medicare boosts reimbursement for NeuroPace’s epilepsy treatment system By Investing.com - Investing.com South Africa
NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services - Investing News Network
Medicare boosts reimbursement for NeuroPace’s epilepsy treatment system - Investing.com
NeuroPace jumps as Medicare boosts pay for epilepsy device procedures - TradingView
NeuroPace Says Medicare Increases Reimbursement for RNS Procedures - marketscreener.com
NeuroPace Inc Stock Analysis and ForecastVolatility Index Analysis & Access High Yield Alerts - earlytimes.in
Can NeuroPace Inc. stock deliver strong Q4 earningsMarket Growth Summary & Real-Time Sentiment Analysis - newser.com
Is NeuroPace Inc. stock gaining market shareBond Market & Consistent Profit Trade Alerts - newser.com
Why NeuroPace Inc. stock could rally in 2025July 2025 Chart Watch & Free Weekly Chart Analysis and Trade Guides - newser.com
Why NeuroPace Inc. stock remains on buy listsMarket Risk Analysis & AI Driven Price Predictions - newser.com
3 Stocks Possibly Trading At A Discount Of Up To 37.8% - Sahm
How rising interest rates impact NeuroPace Inc. stockTrade Signal Summary & Real-Time Stock Price Movement Reports - newser.com
NeuroPace, Inc. Reports Record Revenue and Strong Margins in Q2 2025 Earnings Call - MSN
Neuropace, Inc. Advances in Treating Lennox-Gastaut Syndrome: A Study Update - MSN
How to escape a deep drawdown in NeuroPace Inc.Global Markets & Daily Chart Pattern Signal Reports - newser.com
Revenues Tell The Story For NeuroPace, Inc. (NASDAQ:NPCE) As Its Stock Soars 25% - simplywall.st
Real time alert setup for NeuroPace Inc. performanceJuly 2025 Gainers & Low Drawdown Investment Strategies - newser.com
뉴로페이스 (NPCE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):